JP2000509394A5 - - Google Patents

Download PDF

Info

Publication number
JP2000509394A5
JP2000509394A5 JP1997539221A JP53922197A JP2000509394A5 JP 2000509394 A5 JP2000509394 A5 JP 2000509394A5 JP 1997539221 A JP1997539221 A JP 1997539221A JP 53922197 A JP53922197 A JP 53922197A JP 2000509394 A5 JP2000509394 A5 JP 2000509394A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997539221A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000509394A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/007335 external-priority patent/WO1997040854A2/en
Publication of JP2000509394A publication Critical patent/JP2000509394A/ja
Publication of JP2000509394A5 publication Critical patent/JP2000509394A5/ja
Ceased legal-status Critical Current

Links

JP9539221A 1996-05-01 1997-04-30 細胞膜を横切って物質を輸送するためのポリペプチド結合体 Ceased JP2000509394A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1634796P 1996-05-01 1996-05-01
US60/016,347 1996-05-01
US2860996P 1996-10-23 1996-10-23
US60/028,609 1996-10-23
PCT/US1997/007335 WO1997040854A2 (en) 1996-05-01 1997-04-30 Polypeptide conjugates for transporting substances across cell membranes

Publications (2)

Publication Number Publication Date
JP2000509394A JP2000509394A (ja) 2000-07-25
JP2000509394A5 true JP2000509394A5 (enExample) 2004-12-09

Family

ID=26688485

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9539221A Ceased JP2000509394A (ja) 1996-05-01 1997-04-30 細胞膜を横切って物質を輸送するためのポリペプチド結合体

Country Status (5)

Country Link
EP (1) EP0966303A2 (enExample)
JP (1) JP2000509394A (enExample)
AU (1) AU729643B2 (enExample)
CA (1) CA2252706A1 (enExample)
WO (1) WO1997040854A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032467A2 (en) * 1997-01-24 1998-07-30 Antivirals, Inc. Method and conjugate for treating h. pylori infection
WO1998035703A2 (en) * 1997-02-14 1998-08-20 The Salk Institute For Biological Studies Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
AU734827B2 (en) 1997-05-21 2001-06-21 Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US20020064520A1 (en) * 1999-08-19 2002-05-30 Yanina Rozenberg Targeted artificial gene delivery
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6593292B1 (en) 1999-08-24 2003-07-15 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US6841542B2 (en) 2000-07-06 2005-01-11 Avi Biopharma, Inc. Transforming growth factor beta (TGF-β) blocking agent-treated stem cell composition and method
CA2797652C (en) 2000-07-21 2016-03-08 Revance Therapeutics, Inc. Multi-component biological transport systems
WO2003079972A2 (en) * 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
JP2004523480A (ja) * 2000-08-22 2004-08-05 ニュー リバー ファーマシューティカルズ, インコーポレイテッド 活性作用物質送達系ならびに活性作用物質の保護および投与方法
JP2006516948A (ja) * 2000-11-14 2006-07-13 ニュー リバー ファーマシューティカルズ インコーポレイテッド 硫酸アバカビルを含有する新規な薬剤化合物および同化合物の製造ならびに使用方法
MXPA05007322A (es) 2003-01-06 2006-02-17 Angiochem Inc Aprotinina y analogos como portadores a traves de la barrera sangre-cerebro.
CA2553104A1 (en) 2004-01-23 2005-08-11 Avi Biopharma, Inc. Antisense oligomers and methods for inducing immune tolerance and immunosuppression
WO2005120546A2 (en) 2004-03-03 2005-12-22 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1766012B1 (en) 2004-07-02 2011-05-25 AVI BioPharma, Inc. Antisense antibacterial method and compound
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
ATE551422T1 (de) 2005-02-18 2012-04-15 Angiochem Inc Aprotininpolypeptide zum transport einer verbindung durch die blut-hirn-schranke
US9180081B2 (en) 2005-03-03 2015-11-10 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
CA2599016A1 (en) 2005-03-03 2006-09-08 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of an oligopeptide
AU2006267051B2 (en) 2005-07-13 2013-03-07 Sarepta Therapeutics, Inc. Antisense antibacterial method and compound
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
ES2744225T3 (es) 2005-07-15 2020-02-24 Angiochem Inc Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
EP1935434A1 (en) * 2006-12-19 2008-06-25 Novosom AG Construction and use of transfection enhancer elements
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
ES2665017T3 (es) 2008-03-20 2018-04-24 University Of Florida Research Foundation, Inc. Mejorar el potencial de retorno y reparación de células madre en lesiones vasculares
EP2143726A1 (en) * 2008-07-11 2010-01-13 Novosom AG Nucleic acid comprising zwitterionic nucleotides
RU2011118056A (ru) 2008-10-15 2012-11-27 Ангиокем Инк. Конъюгаты агонистов glp-1 и их применение
CN102307904A (zh) 2008-12-05 2012-01-04 安吉奥开米公司 神经降压素或神经降压素类似物的缀合物及其用途
EP2376633A1 (en) * 2008-12-17 2011-10-19 AVI BioPharma, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
AU2010256445B2 (en) 2009-06-05 2015-07-30 13Therapeutics, Inc. Immunoregulatory peptides and methods of use
CN102596993A (zh) 2009-07-02 2012-07-18 安吉奥开米公司 多聚体肽结合物以及其应用
KR102095478B1 (ko) 2010-05-28 2020-04-01 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
WO2012138879A2 (en) 2011-04-06 2012-10-11 13Therapeutics, Inc. Peptides for the treatment of hearing
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
KR102142689B1 (ko) 2011-11-18 2020-08-10 사렙타 쎄러퓨틱스, 인코퍼레이티드 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트
BR112014023347A2 (pt) 2012-03-20 2017-07-18 Sarepta Therapeutics Inc conjugados de ácido borônico de análogos oligonucleotídeos
GB201210358D0 (en) * 2012-06-12 2012-07-25 Polytherics Ltd Complexes
WO2014026283A1 (en) 2012-08-14 2014-02-20 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
CA3000868C (en) * 2015-10-07 2025-02-04 Cormedix Inc. SKIN PENETRATION FORMULATION BASED ON TAUROLIDINE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
GB9017024D0 (en) * 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
GB9026491D0 (en) * 1990-12-05 1991-01-23 Erba Carlo Spa Anthracycline-conjugates
JP3737518B2 (ja) * 1996-03-12 2006-01-18 ピージー−ティーエックスエル カンパニー, エル.ピー. 水溶性パクリタキセルプロドラッグ

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000501018A5 (enExample)
JP2000500076A5 (enExample)
JP2001501490A5 (enExample)
JP2001500986A5 (enExample)
JP2000501324A5 (enExample)
JP2000515705A5 (enExample)
JP2000500055A5 (enExample)
JP2000500026A5 (enExample)
JP2001500878A5 (enExample)
JP2000502472A5 (enExample)
JP2000501338A5 (enExample)
JP2000500874A5 (enExample)
JP2000509394A5 (enExample)
JP2000502485A5 (enExample)
JP2000502425A5 (enExample)
JP2000517213A5 (enExample)
JP2000502568A5 (enExample)
JP2000500912A5 (enExample)
JP2000502570A5 (enExample)
JP2000501876A5 (enExample)
JP2001503025A5 (enExample)
JP2000501229A5 (enExample)
JP2000502316A5 (enExample)
JP2000500857A5 (enExample)